This Article is From Nov 20, 2017

Cadila Gets USFDA's Final Nod To Market Ethacrynate Sodium

Cadila Healthcare shares trade (at 11.55 am) at Rs 450.50, 0.93% higher than the previous session's closing on BSE

Cadila Gets USFDA's Final Nod To Market Ethacrynate Sodium

Cadila Healthcare shares rise on Monday

Zydus Cadila has recieved the final approval from the USFDA (US Food and Drug Administration) to market Ethacrynate sodium for injection USP, 50 mg/ vial. the drug is used to decrease the swelling caused by various disease conditions such as liver disease, kidney disease, congestive heart failure, cancer and will be produced at the group's formulations manufacuring facility at Moraiya, Ahmedabad.

Cadila Healthcare shares trade (at 11.55 am) at Rs 450.50, 0.93% higher than the previous session's closing on BSE. At NSE, the scrip traded at Rs 450.50, 0.79% higher than the previous session's closing.

.